Prehospital statin and aspirin use and the prevalence of severe sepsis and acute lung injury/acute respiratory distress syndrome

Critical Care Medicine

Volumn 39, Issue 6, 2011, Pages 1343-1350

  O'Neal, Hollis R ^a   Koyama, Tatsuki ^b   Koehler, Elizabeth A S ^b   Siew, Edward ^c   Curtis, Blake R ^d   Fremont, Richard D ^e   May, Addison K ^b   Bernard, Gordon R ^d   Ware, Lorraine B ^d  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b Divisions of Nephrology ^*  (United States)

^c Departments of Medicine   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e MEHARRY MEDICAL COLLEGE   (United States)

Author keywords

acute lung injury; acute respiratory distress syndrome; aspirin; inflammation; sepsis; severe sepsis; statin

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; PRAVASTATIN; SIMVASTATIN; STATIN;

ACUTE LUNG INJURY; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGE; AGED; APACHE; ARTICLE; CRITICAL ILLNESS; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; EMERGENCY CARE; FEMALE; GENDER; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RACE; SEPSIS; SMOKING; TERTIARY HEALTH CARE;

EID: 79957635355     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3182120992     Document Type: Article

References (55)

1. Rubenfeld GD, Caldwell E, Peabody E, et al: Incidence and outcomes of acute lung injury. N Engl J Med 2005; 353:1685-1693. (Pubitemid 41464707)
2. Ashbaugh DG, Bigelow DB, Petty TL, et al: Acute respiratory distress in adults. Lancet 1967; ii:319-323.
3. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med 2000; 342: 1301-1308.
4. Bernard GR, Vincent JL, Laterre PF, et al: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709. (Pubitemid 32204987)
5. Hotchkiss RS, Karl IE: The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348:138-150. (Pubitemid 36056721)
6. Ware LB, Matthay MA: The acute respiratory distress syndrome. N Engl J Med 2000; 342: 1334-1349. (Pubitemid 30408719)
7. Park, WY, Goodman RB, Steinberg KP, et al: Cytokine balance in the lungs of patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 2001; 164: 1896-1903. (Pubitemid 33152327)
8. Ketoconazole for early treatment of acute lung injury and acute respiratory distress syndrome: A randomized controlled trial. The ARDS Network. JAMA 2000; 283: 1995-2002.
9. Randomized, placebo-controlled trial of lisofylline for early treatment of acute lung injury and acute respiratory distress syndrome. Crit Care Med 2002; 30:1-6.
10. Steinberg KP, Hudson LD, Goodman RB, et al: Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med 2006; 354:1671-1684.
11. Bernard GR, Wheeler AP, Russell JA, et al: The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Engl J Med 1997; 336:912-918. (Pubitemid 27137191)
12. Cohen J, Carlet J: INTERSEPT: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med 1996; 24:1431-1440. (Pubitemid 26313741)
13. Redberg RF, Benjamin EJ, Bittner V, et al: ACCF/AHA 2009 performance measures for primary prevention of cardiovascular disease in adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures for Primary Prevention of Cardiovascular Disease) developed in collaboration with the American Academy of Family Physicians; American Association of Cardiovascular and Pulmonary Rehabilitation; and Preventive Cardiovascular Nurses Association: Endorsed by the American College of Preventive Medicine, American College of Sports Medicine, and Society for Women's Health Research. J Am Coll Cardiol 2009; 54:1364-1405.
14. AHA, ACC, National Heart, Lung, and Blood Institute, et al: AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol 2006; 47:2130-2139.
15. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebocontrolled trial. Lancet 2002; 360:7-22.
16. Albert MA, Danielson E, Rifai N, et al: Effect of statin therapy on C-reactive protein levels: The pravastatin inflammation/CRP evaluation (PRINCE): A randomized trial and cohort study. JAMA 2001; 286:64-70. (Pubitemid 32606333)
17. Halcox JP, Deanfield JE: Beyond the laboratory: Clinical implications for statin pleiotropy. Circulation 2004; 109(Suppl 1): 1142-1148.
18. McCarey DW, McInnes IB, Madhok R, et al: Trial of Atorvastatin in Rheumatoid Arthritis (TARA): Double-blind, randomised placebocontrolled trial. Lancet 2004; 363:2015-2021. (Pubitemid 38781100)
19. Vollmer T, Durkalski V, Tyor W, et al: Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 2004; 363: 1607-1608. (Pubitemid 38625664)
20. Novack V, Eisinger M, Frenkel A, et al: The effects of statin therapy on inflammatory cytokines in patients with bacterial infections: A randomized double-blind placebo controlled clinical trial. Intensive Care Med 2009; 35:1255-1260.
21. Graaf MR, Beiderbeck AB, Egberts AC, et al: The risk of cancer in users of statins. J Clin Oncol 2004; 22:2388-2394. (Pubitemid 41115396)
22. Friis S, Poulsen AH, Johnsen SP, et al: Cancer risk among statin users: A populationbased cohort study. Int J Cancer 2005; 114: 643-647. (Pubitemid 40349625)
23. Glynn RJ, Danielson E, Fonseca FA, et al: A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009; 360:1851-1861.
24. Almog Y, Shefer A, Novack V, et al: Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 2004; 110: 880-885. (Pubitemid 39096018)
25. Liappis AP, Kan VL, Rochester CG, et al: The effect of statins on mortality in patients with bacteremia. Clin Infect Dis 2001; 33: 1352-1357. (Pubitemid 32955186)
26. Almog Y, Novack V, Eisinger M, et al: The effect of statin therapy on infection-related mortality in patients with atherosclerotic diseases. Crit Care Med 2007; 35:372-378. (Pubitemid 46148524)
27. Christensen S, Thomsen RW, Johansen MB, et al: Preadmission statin use and one-year mortality among patients in intensive care - A cohort study. Crit Care 2010; 14:R29.
28. Jacobson JR, Barnard JW, Grigoryev DN, et al: Simvastatin attenuates vascular leak and inflammation in murine inflammatory lung injury. Am J Physiol Lung Cell Mol Physiol 2005; 288:L1026-L1032. (Pubitemid 40695427)
29. Kor DJ, Iscimen R, Yilmaz M, et al: Statin administration did not influence the progression of lung injury or associated organ failures in a cohort of patients with acute lung injury. Intensive Care Med 2009; 35: 1039-1046.
30. Heffner JE: Platelet-neutrophil interactions in sepsis-Platelet guilt by association? Intensive Care Med 1997; 23:366-368. (Pubitemid 27196963)
31. Heffner JE, Sahn SA, Repine JE: The role of platelets in the adult respiratory distress syndrome. Culprits or bystanders? Am Rev Respir Dis 1987; 135:482-492. (Pubitemid 17012115)
32. Asaduzzaman M, Lavasani S, Rahman M, et al: Platelets support pulmonary recruitment of neutrophils in abdominal sepsis. Crit Care Med 2009; 37:1389-1396.
33. Looney MR, Nguyen JX, Hu Y, et al: Platelet depletion and aspirin treatment protect mice in a two-event model of transfusion-related acute lung injury. J Clin Invest 2009; 119: 3450-3461.
34. Bozza FA, Shah AM, Weyrich AS, et al: Amicus or adversary: Platelets in lung biology, acute injury, and inflammation. Am J Respir Cell Mol Biol 2009; 40:123-134.
35. Thomsen RW, Riis A, Kornum JB, et al: Preadmission use of statins and outcomes after hospitalization with pneumonia: Populationbased cohort study of 29,900 patients. Arch Intern Med 2008; 168:2081-2087.
36. Bone RC, Balk RA, Cerra FB, et al: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101:1644-1655.
37. Bernard GR, Artigas A, Brigham KL, et al: The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994; 149: 818-824. (Pubitemid 24082248)
38. Bernard GR: The Brussels score. Sepsis 1997; 1:43-44.
39. R Development Core Team: R: A Language Environment for Statistical Computing. Vienna, Austria, R Foundation for Statistical Computing, 2009.
40. Hackam DG, Mamdani M, Li P, et al: Statins and sepsis in patients with cardiovascular disease: A population-based cohort analysis. Lancet 2006; 367:413-418. (Pubitemid 43184262)
41. Sacks FM, Pfeffer MA, Moye LA, et al: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335:1001-1009. (Pubitemid 26338729)
42. Ross R: Atherosclerosis-An inflammatory disease. N Engl J Med 1999; 340:115-126.
43. Steiner S, Speidl WS, Pleiner J, et al: Simvastatin blunts endotoxin-induced tissue factor in vivo. Circulation 2005; 111:1841-1846. (Pubitemid 40525151)
44. Pruefer D, Scalia R, Lefer AM: Simvastatin inhibits leukocyte-endothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats. Arterioscler Thromb Vasc Biol 1999; 19: 2894-2900. (Pubitemid 30029815)
45. Szczeklik A, Undas A, Musial J, et al: Antithrombotic actions of statins. Med Sci Monit 2001; 7:1381-1385. (Pubitemid 33134679)
46. Undas A, Brummel-Ziedins KE, Mann KG: Statins and blood coagulation. Arterioscler Thromb Vasc Biol 2005; 25:287-294. (Pubitemid 40189147)
47. Kruger P, Fitzsimmons K, Cook D, et al: Statin therapy is associated with fewer deaths in patients with bacteraemia. Intensive Care Med 2006; 32:75-79. (Pubitemid 43039379)
48. Joyce M, Kelly CJ, Chen G, et al: Pravastatin attenuates lower torso ischaemia-reperfusion- induced lung injury by upregulating constitutive endothelial nitric oxide synthase. Eur J Vasc Endovasc Surg 2001; 21: 295-300. (Pubitemid 32529994)
49. Naidu BV, Woolley SM, Farivar AS, et al: Simvastatin ameliorates injury in an experimental model of lung ischemia-reperfusion. J Thorac Cardiovasc Surg 2003; 126: 482-489. (Pubitemid 37048516)
50. Pirat A, Zeyneloglu P, Aldemir D, et al: Pretreatment with simvastatin reduces lung injury related to intestinal ischemia-reperfusion in rats. Anesth Analg 2006; 102:225-232. (Pubitemid 43038312)
51. Vaughan CJ, Gotto AM Jr: Update on statins: 2003. Circulation 2004; 110:886-892.
52. Istvan ES, Deisenhofer J: Structural mechanism for statin inhibition of HMG-CoA reductase. Science 2001; 292:1160-1164. (Pubitemid 32440937)
53. Pruefer D, Makowski J, Schnell M, et al: Simvastatin inhibits inflammatory properties of Staphylococcus aureus alpha-toxin. Circulation 2002; 106:2104-2110. (Pubitemid 35192817)
54. Ando H, Takamura T, Ota T, et al: Cerivastatin improves survival of mice with lipopolysaccharide- induced sepsis. J Pharmacol Exp Ther 2000; 294:1043-1046. (Pubitemid 30666857)
55. Liuba P, Pesonen E, Forslid A, et al: Protective effects of simvastatin on coronary artery function in swine with acute infection. Atherosclerosis 2006; 186:331-336